RE-LY (Randomized Evaluation of Long-Term Anticoagulant Therapy)
•Transferir como PPT, PDF•
2 gostaram•719 visualizações
- Background: Dabigatran etexilate is one of several oral anticoagulants in clinical trials for the prevention of AF-related thromboembolism, venous thromboembolism, and other conditions for which warfarin had long been the only choice - Population and treatment: 18 113 patients with AF (mean age 71) and at least one other risk factor for stroke Randomized to blinded treatment with dabigatran 110 mg or 150 mg twice a day or unblinded prophylaxis with warfarin adjusted to an INR of 2.0–3.0 - Primary outcome: Stroke/peripheral embolic events See the article at http://www.theheart.org/article/995769.do
![RE-LY (Randomized Evaluation of Long-Term Anticoagulant Therapy) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],MD Ezekowitz (Lankenau Institute for Medical Research, Wynnewood, PA) European Society of Cardiology 2009 Congress](https://image.slidesharecdn.com/newitem3-110706144219-phpapp01/85/rely-randomized-evaluation-of-longterm-anticoagulant-therapy-1-320.jpg)
![Efficacy results at two years ,[object Object],[object Object],RE-LY: Results a. Annualized rates b. p values are for superiority unless otherwise indicated c. For noninferiority Outcome a Dabigatran low dose (%) Dabigatran high dose (%) Warfarin (%) Relative risk (95% CI) for low dose vs warfarin p for low dose b Relative risk (95% CI) for high dose vs warfarin p for high dose b Primary end point 1.53 1.11 1.69 0.91 (0.74–1.11) <0.001 c 0.66 (0.53–0.82) <0.001 Mortality 3.75 3.64 4.13 0.91 (0.80–1.03) 0.13 0.88 (0.77–1.00) 0.051 MI 0.72 0.74 0.53 1.35 (0.98–1.87) 0.07 1.38 (1.00–1.91) 0.048 Hemorrhagic stroke 0.12 0.10 0.38 0.31 (0.17–0.56) <0.001 0.26 (0.14–0.49) <0.001 Major bleeding 2.71 3.11 3.36 0.80 (0.69–0.93) 0.003 0.93 (0.81–1.07) NS](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recomendados
Mais conteúdo relacionado
Mais procurados
Mais procurados (17)
Destaque
Destaque (12)
Semelhante a RE-LY (Randomized Evaluation of Long-Term Anticoagulant Therapy)
Semelhante a RE-LY (Randomized Evaluation of Long-Term Anticoagulant Therapy) (20)
Mais de theheart.org
Mais de theheart.org (20)
Último
Último (20)
RE-LY (Randomized Evaluation of Long-Term Anticoagulant Therapy)
- 3. RE-LY: Commentary* *All comments from RE-LY: Oral antithrombin dabigatran outshines warfarin in atrial fib (http://www.theheart.org/article/995769.do) "The effect of dabigatran in reducing stroke and intracerebral bleeds far outweighed the small increase in MI rate, but this is a question we will be looking into in much more detail." - Dr Michael D Ezekowitz "Dabigatran, I think will be the new gold standard." - Dr Albert L Waldo "An anticoagulant that actually is more effective than warfarin and doesn't have the side effect of increased bleeding? It's almost never happened before, it's remarkable." - Dr Stuart J Connolly (first author)
Notas do Editor
- Background
- Results
- Commentary